Skip to main content
Top
Published in: CEN Case Reports 1/2024

10-05-2023 | Hepatic Encephalopathy | Case Report

Fatal acute portal vein thrombosis associated with hepatic cysts in a patient with autosomal dominant polycystic kidney disease

Authors: Yohei Tsuchida, Yutaka Tsubata, Ryosuke Nozawa, Shuntaro Maruyama, Kouzo Ikarashi, Noriko Saito, Tetsuo Morioka, Takeshi Kamura, Hisaki Shimada, Ichiei Narita

Published in: CEN Case Reports | Issue 1/2024

Login to get access

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) often involves polycystic liver disease (PLD). In severe cases, PLD can develop various complications. However, fatal acute portal vein thrombosis (APVT) associated with PLD has not been reported. A 64-year-old male reported mild consciousness disorder. He had been under maintenance hemodialysis for end-stage renal disease due to ADPKD with PLD. Because of recurring hepatic cyst infections, he had sustained high levels of C-reactive protein. Regarding the mild consciousness disorder, a diagnosis of hepatic encephalopathy was made based on an elevation of serum ammonia without any other abnormal liver function tests. Several days after his admission, hepatobiliary enzymes elevated, and acute liver failure progressed. Enhanced abdominal computed tomography suggested the possibility of complete occlusion of the portal vein by a thrombus. Based on an absence of obvious portosystemic collaterals, a diagnosis of APVT was made. The patient died 19 days after admission. Patients with PLD with repeated cystic infections have been seen to develop liver failure, and APVT formation may be one cause of the rapid progression of fatal liver failure. In conclusion, this is the first paper to report on the involvement of APVT in patients with PLD.
Literature
1.
go back to reference Cornec-Le Gall E, Alam A, Perrone RD. Autosomal dominant polycystic kidney disease. Lancet. 2019;393:919–35.CrossRefPubMed Cornec-Le Gall E, Alam A, Perrone RD. Autosomal dominant polycystic kidney disease. Lancet. 2019;393:919–35.CrossRefPubMed
2.
go back to reference Zhang ZY, Wang ZM, Huang Y. Polycystic liver disease: Classification, diagnosis, treatment process, and clinical management. World J Hepatol. 2020;12:72–83.CrossRefPubMedPubMedCentral Zhang ZY, Wang ZM, Huang Y. Polycystic liver disease: Classification, diagnosis, treatment process, and clinical management. World J Hepatol. 2020;12:72–83.CrossRefPubMedPubMedCentral
4.
go back to reference Gevers TJ, Drenth JP. Diagnosis and management of polycystic liver disease. Nat Rev Gastroenterol Hepatol. 2013;10:101–8.CrossRefPubMed Gevers TJ, Drenth JP. Diagnosis and management of polycystic liver disease. Nat Rev Gastroenterol Hepatol. 2013;10:101–8.CrossRefPubMed
5.
go back to reference Takei R, Ubara Y, Hoshino J, et al. Percutaneous transcatheter hepatic artery embolization for liver cysts in autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2007;49:744–52.CrossRefPubMed Takei R, Ubara Y, Hoshino J, et al. Percutaneous transcatheter hepatic artery embolization for liver cysts in autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2007;49:744–52.CrossRefPubMed
6.
go back to reference Hoshino J, Ubara Y, Suwabe T, et al. Intravascular embolization therapy in patients with enlarged polycystic liver. Am J Kidney Dis. 2014;63:937–44.CrossRefPubMed Hoshino J, Ubara Y, Suwabe T, et al. Intravascular embolization therapy in patients with enlarged polycystic liver. Am J Kidney Dis. 2014;63:937–44.CrossRefPubMed
7.
go back to reference Suwabe T, Araoka H, Ubara Y, et al. Cyst infection in autosomal dominant polycystic kidney disease: causative microorganisms and susceptibility to lipid-soluble antibiotics. Eur J Clin Microbiol Infect Dis. 2015;34:1369–79.CrossRefPubMed Suwabe T, Araoka H, Ubara Y, et al. Cyst infection in autosomal dominant polycystic kidney disease: causative microorganisms and susceptibility to lipid-soluble antibiotics. Eur J Clin Microbiol Infect Dis. 2015;34:1369–79.CrossRefPubMed
8.
go back to reference Suwabe T. Cyst infection in autosomal dominant polycystic kidney disease: our experience at Toranomon Hospital and future issues. Clin Exp Nephrol. 2020;24:748–61.CrossRefPubMedPubMedCentral Suwabe T. Cyst infection in autosomal dominant polycystic kidney disease: our experience at Toranomon Hospital and future issues. Clin Exp Nephrol. 2020;24:748–61.CrossRefPubMedPubMedCentral
10.
go back to reference Ogawa K, Fukunaga K, Takeuchi T, et al. Current treatment status of polycystic liver disease in Japan. Hepatol Res. 2014;44:1110–8.CrossRefPubMed Ogawa K, Fukunaga K, Takeuchi T, et al. Current treatment status of polycystic liver disease in Japan. Hepatol Res. 2014;44:1110–8.CrossRefPubMed
11.
go back to reference Seedial SM, Mouli SK, Desai KR. Acute portal vein thrombosis: current trends in medical and endovascular management. Semin Intervent Radiol. 2018;35:198–202.CrossRefPubMedPubMedCentral Seedial SM, Mouli SK, Desai KR. Acute portal vein thrombosis: current trends in medical and endovascular management. Semin Intervent Radiol. 2018;35:198–202.CrossRefPubMedPubMedCentral
13.
go back to reference Plessier A, Darwish-Murad S, Hernandez-Guerra M, et al. Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. Hepatology. 2010;51:210–8.CrossRefPubMed Plessier A, Darwish-Murad S, Hernandez-Guerra M, et al. Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. Hepatology. 2010;51:210–8.CrossRefPubMed
14.
go back to reference Galante A, De Gottardi A. Portal vein thrombosis: an overview of current treatment options. Acta Gastroenterol Belg. 2021;84:327–32.CrossRefPubMed Galante A, De Gottardi A. Portal vein thrombosis: an overview of current treatment options. Acta Gastroenterol Belg. 2021;84:327–32.CrossRefPubMed
15.
go back to reference DeLeve LD, Valla DC, Garcia-Tsao G. American association for the study liver diseases. Vascular disorders of the liver. Hepatology. 2009;49:1729–64.CrossRefPubMed DeLeve LD, Valla DC, Garcia-Tsao G. American association for the study liver diseases. Vascular disorders of the liver. Hepatology. 2009;49:1729–64.CrossRefPubMed
16.
go back to reference Nery F, Chevret S, Condat B, et al. Causes and consequences of portal vein thrombosis in 1243 patients with cirrhosis: results of a longitudinal study. Hepatology. 2015;61:660–7.CrossRefPubMed Nery F, Chevret S, Condat B, et al. Causes and consequences of portal vein thrombosis in 1243 patients with cirrhosis: results of a longitudinal study. Hepatology. 2015;61:660–7.CrossRefPubMed
17.
go back to reference Torres VE, Rastogi S, King BF, et al. Hepatic venous outflow obstruction in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 1994;5:1186–92.CrossRefPubMed Torres VE, Rastogi S, King BF, et al. Hepatic venous outflow obstruction in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 1994;5:1186–92.CrossRefPubMed
18.
go back to reference Lantinga MA, Drenth JPH, Gevers TJG. Diagnostic criteria in renal and hepatic cyst infection. Nephrol Dial Transplant. 2015;30:744–51.CrossRefPubMed Lantinga MA, Drenth JPH, Gevers TJG. Diagnostic criteria in renal and hepatic cyst infection. Nephrol Dial Transplant. 2015;30:744–51.CrossRefPubMed
19.
go back to reference Kawada M, Hayami N, Suwabe T, et al. Hepatocellular carcinoma in a patient with polycystic liver disease. Intern Med. 2015;54:1891–6.CrossRefPubMed Kawada M, Hayami N, Suwabe T, et al. Hepatocellular carcinoma in a patient with polycystic liver disease. Intern Med. 2015;54:1891–6.CrossRefPubMed
20.
go back to reference Umeshita K, Eguchi S, Egawa H, et al. Liver transplantation in Japan: registry by the Japanese liver transplantation society. Hepatol Res. 2019;49:964–80.CrossRefPubMed Umeshita K, Eguchi S, Egawa H, et al. Liver transplantation in Japan: registry by the Japanese liver transplantation society. Hepatol Res. 2019;49:964–80.CrossRefPubMed
21.
go back to reference Sugimoto H, Oshima Y, Oba Y, et al. Successful case of deceased donor liver transplant for polycystic liver disease. Transplant Proc. 2022;54:2779–83.CrossRefPubMed Sugimoto H, Oshima Y, Oba Y, et al. Successful case of deceased donor liver transplant for polycystic liver disease. Transplant Proc. 2022;54:2779–83.CrossRefPubMed
22.
go back to reference Nery F, Valadares D, Morais S, et al. Efficacy and safety of direct-acting oral anticoagulants use in acute portal vein thrombosis unrelated to cirrhosis. Gastroenterol Res. 2017;10:141–3.CrossRef Nery F, Valadares D, Morais S, et al. Efficacy and safety of direct-acting oral anticoagulants use in acute portal vein thrombosis unrelated to cirrhosis. Gastroenterol Res. 2017;10:141–3.CrossRef
23.
go back to reference Rogula S, Gąsecka A, Mazurek T, et al. Safety and efficacy of DOACs in patients with advanced and end-stage renal disease. Int J Environ Res Public Health. 2022;19:1436.CrossRefPubMedPubMedCentral Rogula S, Gąsecka A, Mazurek T, et al. Safety and efficacy of DOACs in patients with advanced and end-stage renal disease. Int J Environ Res Public Health. 2022;19:1436.CrossRefPubMedPubMedCentral
25.
go back to reference Boike JR, Thornburg BG, Asrani SK, et al. North American practice-based recommendations for Transjugular intrahepatic portosystemic shunts in portal hypertension. Clin Gastroenterol Hepatol. 2022;20:1636–62.CrossRefPubMed Boike JR, Thornburg BG, Asrani SK, et al. North American practice-based recommendations for Transjugular intrahepatic portosystemic shunts in portal hypertension. Clin Gastroenterol Hepatol. 2022;20:1636–62.CrossRefPubMed
Metadata
Title
Fatal acute portal vein thrombosis associated with hepatic cysts in a patient with autosomal dominant polycystic kidney disease
Authors
Yohei Tsuchida
Yutaka Tsubata
Ryosuke Nozawa
Shuntaro Maruyama
Kouzo Ikarashi
Noriko Saito
Tetsuo Morioka
Takeshi Kamura
Hisaki Shimada
Ichiei Narita
Publication date
10-05-2023

Other articles of this Issue 1/2024

CEN Case Reports 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine